Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis.

Front Immunol · 2024 · PMC11349560 · PMID 39206183

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

slightly significantno p-value reported

DCR ( P = 0.30, I 2 = 13%) displayed slightly significant heterogeneity, as per the heterogeneity test.

also in 1,756 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.